险资方向，本期较上一期持股增加的险资共计1个，即中国人寿保险(集团)公司-传统-普通保险产品-港 股通(创新策略)，持股增加占比小幅上涨。本期较上一季度持股减少的险资共计1个，即中国人寿保险 股份有限公司-传统-普通保险产品-005L-CT001沪，持股减少占比小幅下跌。 公募基金方面，本期较上一期持股增加的公募基金共计20个，主要包括南方标普中国A股大盘红利低波 50ETF、汇添富中证主要消费ETF、兴全中证800六个月持有指数增强A、博时中证红利低波100ETF、 宏利消费红利指数A等，持股增加占比达0.31%。本期较上一季度持股减少的公募基金共计22个，主要 包括兴全沪深300指数增强(LOF)A、工银创新动力股票、嘉实沪深300红利低波动ETF、华泰柏瑞沪深 300ETF、景顺长城中证红利低波动100ETF等，持股减少占比达0.19%。本期较上一季度新披露的公募 基金共计15个，主要包括华夏睿磐泰利混合A、广发聚荣一年持有期混合A、长城中证红利低波 100ETF、南方标普中国A股大盘红利低波50ETF联接A、北信瑞丰优选成长等。本期较上一季未再披露 的公募基金共计524个，主要包括易方达沪深300ET ...

Core Points - The announcement is regarding the second dividend distribution for the year 2025 from the "Jia Shi CSI 300 Dividend Low Volatility ETF" [1] - The dividend distribution base date is set for September 9, 2025, with a cash dividend of 1.37 yuan per unit, translating to 0.23 yuan for every 10 units held [1] Dividend Details - The fund code for the ETF is 515300, and the cash dividend will be distributed to all fund unit holders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the end of trading on September 17, 2025 [1] - The cash dividend payment date is scheduled for September 23, 2025, and the distribution method is cash dividends [1] - According to relevant laws and regulations, the fund's dividend distribution is exempt from income tax, and there are no dividend distribution fees [1]

2025年8月13日，双汇发展(000895.SZ)发布2025年半年度报告。截至2025年8月12日，共有56个机构投 资者披露持有双汇发展A股股份，合计持股量达27.93亿股，占双汇发展总股本的80.62%。其中，前十 大机构投资者包括罗特克斯有限公司、中国人寿保险股份有限公司-传统-普通保险产品-005L-CT001 沪、香港中央结算有限公司、中国证券金融股份有限公司、中央汇金资产管理有限责任公司、中国工商 银行股份有限公司-华泰柏瑞沪深300交易型开放式指数证券投资基金、新华人寿保险股份有限公司-传 统-普通保险产品-018L-CT001深、中国建设银行股份有限公司-易方达沪深300交易型开放式指数发起式 证券投资基金、中国人寿保险(集团)公司-传统-普通保险产品-港股通(创新策略)、中国农业银行股份有 限公司-兴全沪深300指数增强型证券投资基金(LOF)，前十大机构投资者合计持股比例达79.60%。相较 于上一季度，前十大机构持股比例合计下跌了0.35个百分点。 外资态度来看，本期较上一季度持股减少的外资基金共计1个，即香港中央结算有限公司，持股减少占 比达0.29%。 险资方向，本期较上一季度持 ...

Summary of Key Points Core Viewpoint - On August 11, style strategy ETFs experienced a net outflow of 694 million yuan, with a cumulative net outflow of 707 million yuan over the past five trading days, indicating a trend of capital withdrawal from these funds [1]. Fund Performance - A total of 15 style strategy ETFs saw net inflows on the same day, with the highest inflow recorded for the Bosera National Index Large Cap Value ETF (159391), which increased by 99 million shares and had a net inflow of 111 million yuan [1][3]. - Conversely, 17 style strategy ETFs experienced net outflows, with the Huatai-PB CSI Dividend Low Volatility ETF (512890) leading the outflows, decreasing by 369 million shares and resulting in a net outflow of 443 million yuan [1][4]. Detailed Fund Data - The top 10 ETFs by net outflow on August 11 included: - Huatai-PB CSI Dividend Low Volatility ETF (512890): -443 million yuan, -369 million shares - Huatai-PB SSE Dividend ETF (510880): -232 million yuan, -71 million shares - Harvest CSI 300 Dividend Low Volatility ETF (515300): -117 million yuan, -84 million shares - Southern Dividend Low 50 ETF (515450): -97 million yuan, -68 million shares - Others included various ETFs with smaller outflows [4][5]. Overall Market Trends - The overall trend indicates a cautious sentiment among investors in the style strategy ETF segment, as evidenced by the significant net outflows and the mixed performance of individual funds [1][4].

Stock Recommendations - Donghua Testing (300354.SZ) shows strong order fulfillment and is expected to benefit from its advanced sensor capabilities, with an EPS forecast of 1.22 in 2025, up from 0.88 in 2024[3] - Daotong Technology (688208.SH) reported a 26.71% revenue growth in Q1 2025 and a 57.50% increase in net profit, maintaining a high growth trajectory[3] - Shuanghuan Transmission (002472.SZ) is expected to see continued growth in its core business driven by new energy and smart execution mechanisms, with an EPS forecast of 1.59 in 2025[3] Financial Performance Highlights - Xinyiseng (300502.SZ) achieved a revenue of 86.47 billion yuan in 2024, a 179.15% increase year-on-year, and a net profit of 28.38 billion yuan, up 312.26%[4] - Kexing Pharmaceutical (688136.SH) expanded its overseas sales network, with a projected EPS of 0.51 in 2025, significantly up from 0.16 in 2024[3] - Kaiying Network (002517.SZ) reported a revenue of 51.18 billion yuan in 2024, a 19.16% increase, and a net profit of 16.28 billion yuan, up 11.41%[5] Market Trends and Valuation - The market performance of the recommended stocks shows that Kexing Pharmaceutical had the highest increase of over 50% in the last month, while Xinyiseng and Donghua Testing had turnover rates exceeding 100%[20] - The average PE ratio for the recommended stocks is below 50, with Kexing Pharmaceutical having the highest at 170.61, indicating a potential for growth despite high valuation[20] - The largest market capitalization among the recommended stocks is for Juzhi Biological (2367.HK) at 795.15 billion yuan, followed by Xinyiseng at 636.44 billion yuan[20]